Praxis Precision Medicines
PRAX
150 hedge funds and large institutions have $889M invested in Praxis Precision Medicines in 2025 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 47 increasing their positions, 53 reducing their positions, and 45 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
0.2% less ownership
Funds ownership: 116.53% → 116.33% (-0.2%)
7% less funds holding
Funds holding: 162 → 150 (-12)
11% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 53
22% less call options, than puts
Call options by funds: $17.8M | Put options by funds: $22.8M
27% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 45
47% less capital invested
Capital invested by funds: $1.67B → $889M (-$782M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$71.1M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$56M |
| 3 |
DM
Deerfield Management
New York
|
+$38.7M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$36M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$28.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$58.6M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$23.3M |
| 3 |
PA
Perceptive Advisors
New York
|
-$21.8M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$18.2M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$16.5M |
PRAX Hedge Fund Activity: Q1 2025 in Review
150 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q1 2025, worth a combined $889M — down 47% from $1.67B a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of PRAX and 33 opened new positions — a net loss of 12 holders — while 53 trimmed existing stakes and 47 added.
The largest buyer was Adage Capital Partners, adding an estimated $71.1M. The largest seller was RA Capital Management, exiting entirely with an estimated $58.6M sold.
- 150 institutional investors held Praxis Precision Medicines (PRAX) as of Q1 2025, down from 162 in Q4 2024.
- Funds reported $889M of Praxis Precision Medicines stock for Q1 2025, down 47% quarter-over-quarter.
- 33 funds opened new Praxis Precision Medicines positions in Q1 2025 and 45 closed out, a net change of -12 holders.
- The largest Praxis Precision Medicines buyer in Q1 2025 was Adage Capital Partners, an estimated $71.1M added.
- The largest Praxis Precision Medicines seller in Q1 2025 was RA Capital Management, an estimated $58.6M sold.
Based on aggregated 13F filings for Q1 2025.